Publications by authors named "Anna Tallman"

Claim this Profile
T
Tapinarof cream 1% once daily was well tolerated in adults and children with atopic dermatitis in two phase 3 randomized trials.
Linda Stein Gold, James Del Rosso, Benjamin D Ehst, Matthew J Zirwas, Lawrence J Green, Anna M Tallman

J Dermatolog Treat· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitis.
Robert Bissonnette, Linda Stein Gold, Leon Kircik, Eric L Simpson, Lawrence F Eichenfield, Anna M Tallman

J Am Acad Dermatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tapinarof Cream for Adults and Children with Atopic Dermatitis-Efficacy by Race and Fitzpatrick Skin Type in Two Phase 3 Randomized Clinical Trials.
Andrew F Alexis, Leon Kircik, Raj Chovatiya, Zakiya P Rice, Weily Soong, Anna M Tallman

Dermatol Ther (Heidelb)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid Onset of Itch Relief With Tapinarof in Two Phase 3 Trials in Atopic Dermatitis.
Eric L Simpson, Jonathan I Silverberg, Robert Bissonnette, Linda Stein Gold, April Armstrong, Anna M Tallman

J Drugs Dermatol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children.
Eric L Simpson, Adelaide A Hebert, John Browning, Rocco T Serrao, Howard Sofen, Anna M Tallman

Dermatol Ther (Heidelb)· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treat-to-Target Outcomes With Tapinarof Cream 1% in Phase 3 Trials for Plaque Psoriasis.
April W Armstrong, Robert Bissonnette, Raj Chovatiya, Tina Bhutani, Philip M Brown, Anna M Tallman

Cutis· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials.
Jonathan I Silverberg, Lawrence F Eichenfield, Adelaide A Hebert, Eric L Simpson, Linda Stein Gold, Anna M Tallman

J Am Acad Dermatol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tapinarof validates the aryl hydrocarbon receptor as a therapeutic target: A clinical review.
Jonathan I Silverberg, Mark Boguniewicz, Francisco J Quintana, Rachael A Clark, Lara Gross, Anna M Tallman

J Allergy Clin Immunol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the Aryl Hydrocarbon Receptor to Address the Challenges of Atopic Dermatitis.
Lawrence F Eichenfield, Jonathan I Silverberg, Adelaide A Hebert, Raj Chovatiya, Philip M Brown, Anna M Tallman

J Drugs Dermatol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid Improvements in Itch with Tapinarof Cream 1% Once Daily in Two Phase 3 Trials in Adults with Mild to Severe Plaque Psoriasis.
Leon Kircik, Matthew Zirwas, Shawn G Kwatra, G Michael Lewitt, Holly Glover, Anna M Tallman

Dermatol Ther (Heidelb)· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tapinarof cream 1% once daily for the treatment of plaque psoriasis: Patient-reported outcomes from the PSOARING 3 trial.
Jerry Bagel, Linda Stein Gold, James Del Rosso, Sandy Johnson, Paul Yamauchi, Anna M Tallman

J Am Acad Dermatol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tapinarof Cream 1% Once Daily for the Treatment of Plaque Psoriasis: Case Photography of Clinical Outcomes from Three Phase 3 Trials.
Seemal R Desai, Linda Stein Gold, Michael C Cameron, Alexandra Golant, G Michael Lewitt, Anna M Tallman

Dermatol Ther (Heidelb)· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tapinarof, a Novel, First-in-Class, Topical Therapeutic Aryl Hydrocarbon Receptor Agonist for the Management of Psoriasis.
Margaret Bobonich, Joe Gorelick, Lakshi Aldredge, Matthew J Bruno, Douglas DiRuggiero, Anna M Tallman

J Drugs Dermatol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial.
Bruce Strober, Linda Stein Gold, Robert Bissonnette, April W Armstrong, Leon Kircik, Anna M Tallman

J Am Acad Dermatol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.
Mark G Lebwohl, Linda Stein Gold, Bruce Strober, Kim A Papp, April W Armstrong, Anna M Tallman

N Engl J Med· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tapinarof cream 1% once daily and benvitimod 1% twice daily are 2 distinct topical medications.
Linda Stein Gold, David S Rubenstein, Ken Peist, Piyush Jain, Anna M Tallman

J Am Acad Dermatol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD.
Rebecca Hall, Mark G Lebwohl, Andrew G Bushmakin, Eric L Simpson, Melinda J Gooderham, Anna M Tallman

Dermatol Ther (Heidelb)· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1b, Randomized, Single-Center Trial of Topical Cerdulatinib (DMVT-502) in Patients with Mild-to-Moderate Atopic Dermatitis.
Stephen C Piscitelli, Ana B Pavel, Kimberly McHale, John E Jett, Jon Collins, Anna M Tallman

J Invest Dermatol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tapinarof-associated folliculitis is generally mild, self-limiting, and rarely interferes with therapy.
Robert Bissonnette, Linda Stein Gold, David S Rubenstein, Anna M Tallman, April W Armstrong

J Am Acad Dermatol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The preponderance of evidence supports an aryl hydrocarbon receptor-dependent mechanism of action of tapinarof.
Robert Bissonnette, Linda Stein Gold, David S Rubenstein, Anna M Tallman, April W Armstrong

J Am Acad Dermatol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent.
Robert Bissonnette, Linda Stein Gold, David S Rubenstein, Anna M Tallman, April Armstrong

J Am Acad Dermatol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: Secondary efficacy and patient-reported outcomes.
Linda Stein Gold, Neal Bhatia, Anna M Tallman, David S Rubenstein

J Am Acad Dermatol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis.
Amy S Paller, Linda Stein Gold, Jennifer Soung, Anna M Tallman, David S Rubenstein

J Am Acad Dermatol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD.
Rebecca Hall, Mark G Lebwohl, Andrew G Bushmakin, Eric L Simpson, Melinda J Gooderham, Anna M Tallman

Dermatol Ther (Heidelb)· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the Efficacy of Crisaborole Using the Atopic Dermatitis Severity Index and Percentage of Affected Body Surface Area.
Jonathan I Silverberg, Anna M Tallman, William C Ports, Robert A Gerber, Huaming Tan

Acta Derm Venereol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis